Radiological complete response as a prognostic marker in HR-positive metastatic breast cancer treated with CDK4/6 inhibitors: Implications for treatment de-escalation

A retrospective analysis of 178 patients with HR+ metastatic breast cancer treated with CDK4/6 inhibitors investigated clinicopathological factors for their associations with radiological complete response. The investigators found that radiological complete response following CDK4/6 inhibitor therapy was an independent prognostic factor in this patient population and that patients with smaller primary tumors and those who received early administration of abemaciclib were more likely to achieve radiological complete response.